Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Joseph M. Klausner

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5058701953. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 12

  1. The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuva… Co-author DOI 10.3390/jcm13175206↗
  2. Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Co-author DOI 10.3390/cancers15113049↗
  3. Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surge.2019.07.003↗
  4. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08469-8↗
  5. Protective Desmoplasia in Pancreatic Adenocarcinoma: High Vitamin D Receptor Expression and Collagen Content. Co-author DOI 10.21873/anticanres.14667↗
  6. Desmoplasia in Lymph Node Metastasis of Pancreatic Adenocarcinoma Reveals Activation of Cancer-Associated Fibroblasts Pattern and T-helper 2 Immune Cell Infilt… Last author DOI 10.1097/mpa.0000000000001261↗
  7. MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. Co-author DOI 10.18632/oncotarget.26804↗
  8. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Co-author DOI 10.1016/j.ejso.2018.07.057↗
  9. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival. Last author DOI 10.1245/s10434-017-6237-0↗
  10. ASO Author Reflections: Even in Pancreatic Cancer, not all N Diseases are Created Equal. Last author DOI 10.1245/s10434-018-6813-y↗
  11. Unique cellular interactions between pancreatic cancer cells and the omentum. Co-author DOI 10.1371/journal.pone.0179862↗
  12. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology… Last author DOI 10.1186/s12957-016-0983-5↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guy Lahat · 11 shared papers, 2016–2023 · strength 1.13
  2. Nir Lubezky · 8 shared papers, 2016–2024 · strength 0.90
  3. Ido Wolf · 7 shared papers, 2016–2023 · strength 0.70
  4. Eran Nizri‏ · 6 shared papers, 2016–2020 · strength 0.59
  5. Alex Barenboim · 4 shared papers, 2018–2024 · strength 0.56
  6. Ido Nachmany · 4 shared papers, 2016–2020 · strength 0.34
  7. Yossi Maman · 1 shared paper, 2023 · strength 0.18
  8. Uri Neeman · 1 shared paper, 2020 · strength 0.11
  9. Adi Vaknine Bahat · 1 shared paper, 2020 · strength 0.11
  10. Moran Lemberger · 1 shared paper, 2019 · strength 0.10
  11. Talia Golan · 1 shared paper, 2020 · strength 0.10
  12. Valerya Feygenzon · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.